Drug development: Raise standards for preclinical cancer research

Nature

Volumn 483, Issue 7391, 2012, Pages 531-533

  Begley, C Glenn ^a   Ellis, Lee M ^b  

^a AMGEN INC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; DRUG DEVELOPMENT; PUBLISHING; RESEARCH WORK;

ARTICLE; CANCER RESEARCH; CLINICAL RESEARCH; EXPERIMENTAL DESIGN; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PUBLICATION; RESEARCH ETHICS; STANDARD; VALIDATION PROCESS;

ANIMALS; BIOMEDICAL RESEARCH; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; NEOPLASMS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT FAILURE;

EID: 84859169880     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/483531a     Document Type: Article

References (5)

1. Hutchinson, L. & Kirk, R. Nature Rev. Clin. Oncol. 8, 189-190 (2011).
2. Francia, G. & Kerbel, R. S. Nature Biotechnol. 28, 561-562 (2010).
3. Rubin, E. H. & Gilliland, D. G. Nature Rev. Clin. Oncol. http://dx.doi.org/10.1038/nrclinonc.2012.22 (2012).
4. Prinz, F., Schlange, T. & Asadullah, K. Nature Rev. Drug Discov. 10, 712 (2011).
5. Fanelli, D. PLoS ONE 5, e10271 (2010).